Abstract

The essay examines the relationship of public authorities with Big Pharma about the profile of access to the drug and understand what the problems are inherent in the pricing of medicines. Furthermore, the contribution studies how in EU the pharmaceutical companies influence the drugs pricing through existing regulations and why such legislation does not allow public authorities – national drug agencies – to setting fair prices by facilitating access to the drug for patients. Finally, the contribution will analyze the EU supranational law remedies to counter the excessive pricing of drugs and to limit the influence of Big Pharma.